Sensus Healthcare (NASDAQ:SRTS) Downgraded by Wall Street Zen to Sell

Wall Street Zen lowered shares of Sensus Healthcare (NASDAQ:SRTS - Free Report) from a hold rating to a sell rating in a research note issued to investors on Sunday.

SRTS has been the topic of a number of other research reports. Lake Street Capital decreased their target price on Sensus Healthcare from $18.00 to $13.00 and set a "buy" rating on the stock in a research report on Tuesday, March 11th. HC Wainwright reissued a "buy" rating and issued a $12.00 price objective on shares of Sensus Healthcare in a research note on Friday, April 4th. Finally, Maxim Group reduced their price objective on Sensus Healthcare from $14.00 to $10.00 and set a "buy" rating for the company in a research note on Monday, May 19th. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $11.67.

Sensus Healthcare Stock Performance

NASDAQ SRTS traded down $0.01 during trading hours on Friday, reaching $4.73. The stock had a trading volume of 55,435 shares, compared to its average volume of 194,832. The stock has a fifty day moving average of $4.68 and a 200 day moving average of $5.61. The stock has a market cap of $77.76 million, a P/E ratio of 47.30 and a beta of 1.32. Sensus Healthcare has a 52-week low of $4.01 and a 52-week high of $9.33.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.20). Sensus Healthcare had a return on equity of 3.34% and a net margin of 4.56%. The company had revenue of $8.34 million during the quarter, compared to analysts' expectations of $7.23 million. On average, equities research analysts forecast that Sensus Healthcare will post 0.32 EPS for the current year.

Institutional Trading of Sensus Healthcare

A number of hedge funds and other institutional investors have recently modified their holdings of SRTS. Larson Financial Group LLC purchased a new position in Sensus Healthcare during the 1st quarter valued at about $26,000. JPMorgan Chase & Co. purchased a new position in shares of Sensus Healthcare in the 4th quarter valued at about $27,000. Barclays PLC purchased a new position in shares of Sensus Healthcare in the 4th quarter valued at about $35,000. BNP Paribas Financial Markets purchased a new position in shares of Sensus Healthcare in the 4th quarter valued at about $47,000. Finally, Chapin Davis Inc. boosted its stake in shares of Sensus Healthcare by 50.0% in the 1st quarter. Chapin Davis Inc. now owns 15,000 shares of the company's stock valued at $71,000 after buying an additional 5,000 shares during the period. 25.30% of the stock is owned by institutional investors and hedge funds.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.